Iwata, Hiroji http://orcid.org/0000-0002-0242-4718
Saji, Shigehira
Ikeda, Masahiko
Inokuchi, Masashi
Uematsu, Takayoshi
Toyama, Tatsuya
Horii, Rie
Yamauchi, Chikako
Article History
Received: 10 October 2019
Accepted: 31 October 2019
First Online: 22 November 2019
Change Date: 19 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-021-01253-w
Compliance with ethical standards
:
: Hiroji Iwata received research funding from Chugai, Novartis, MSD, and Lilly and honoraria from Chugai, AstraZeneca, and Daiichi Sankyo and serves as an advisory board to Daiichi Sankyo, Chugai, Lilly, Kyowa Hakko Kirin, Pfizer, Novartis, and AstraZeneca. Shigehira Saji received research funding from Chugai, AstraZeneca, Eisai, Takeda, Novartis, Taiho, Nihon Kayaku, and Ono; honoraria from Chugai, AstraZeneca, Eisai, Takeda, Novartis, Taiho, Nihon Kayaku, Kyowa Kirin, Pfizer, and Daiichi-Sankyo and serves as an advisory board to Chugai, Kyowa Kirin, and Novartis. Masahiko Ikeda received research funding from Hisamitsu and honoraria from Chugai, Daiichi Sankyo, Kyowa Hakko Kirin, and Pfizer. Tatsuya Toyama received research funding from Chugai, AstraZeneca, Eisai, and Novartis and honoraria from Chugai, AstraZeneca, Eisai, Novartis, Lilly, Kyowa Kirin, Taiho, Daiichi-Sankyo, Takeda, Nihon Kayaku, and Pfizer. Rie Horii received honoraria from Chugai, Roche Diagnostics, AstraZeneca, Taiho, Takeda, Pfizer, and Eisai and serves as advisory board to Chugai. Masashi Inokuchi, Takayoshi Uematsu, and Chikako Yamauchi have no conflicts of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.